Abstract:Extracellular vesicles (EVs) are involved in the pathogenesis of neoplastic diseases. Their role in mediating drug resistance has been widely described in several types of cancers, including melanoma. EVs can mediate drug resistance through several different mechanisms, such as drug-sequestration, transfer of pro-survival proteins and RNA, induction of cancer stem cell-like features and interaction with cells of the tumor microenvironment and immune-system. Melanoma is a highly immunogenic tumor originating from the malignant transformation of melanocytes. Several therapeutic strategies currently used in the treatment of melanoma and the combination of BRAF and MEK-inhibitors, as well as immune check-point inhibitors (ICI), have consistently improved the overall survival time of melanoma patients. However, the development of resistance is one of the biggest problems leading to a poor clinical outcome, and EVs can contribute to this. EVs isolated from melanoma cells can contain “sequestered” chemotherapeutic drugs in order to eliminate them, or bioactive molecules (such as miRNA or proteins) that have been proven to play a crucial role in the transmission of resistance to sensitive neoplastic cells. This leads to the hypothesis that EVs could be considered as resistance-mediators in sensitive melanoma cells. These findings are a pivotal starting point for further investigations to better understand EVs’ role in drug resistance mechanisms and how to target them. The purpose of this review is to summarize knowledge about EVs in order to develop a deeper understanding of their underlying mechanisms. This could lead to the development of new therapeutic strategies able to bypass EV-mediated drug-resistance in melanoma, such as by the use of combination therapy, including EV release inhibitors.

Microbial extracellular vesicles contribute to antimicrobial resistance

The role of bacterial extracellular vesicles in promoting antibiotic resistance

Extracellular vesicles in anti-tumor drug resistance: Mechanisms and therapeutic prospects

Extracellular Vesicles in Cancer Drug Resistance: Roles, Mechanisms, and Implications

Intercellular transfer of multidrug resistance mediated by extracellular vesicles

Exosome Mediated Multidrug Resistance in Cancer.

Extracellular Vesicles: Recent Insights Into the Interaction Between Host and Pathogenic Bacteria

The Role of Intracellular and Extracellular Vesicles in the Development of Therapy Resistance in Cancer

The Role of Bacterial Extracellular Vesicles in the Immune Response to Pathogens, and Therapeutic Opportunities

Exploring bacterial extracellular vesicles: Focus on WHO critical priority pathogens

Bacterial Extracellular Vesicles and the Spread of Antibiotic Resistance in Aquatic Environments

Extracellular Vesicles in Cancer Drug Resistance: Implications on Melanoma Therapy

Role of Extracellular Vesicles in Viral and Bacterial Infections: Pathogenesis, Diagnostics, and Therapeutics

Microbial Extracellular Vesicles in Host-Microbiota Interactions

[Research progress on the role of extracellular vesicles in bacterial pathogenesis].

The application of extracellular vesicles in colorectal cancer metastasis and drug resistance: recent advances and trends

Hidden allies: how extracellular vesicles drive biofilm formation, stress adaptation, and host–immune interactions in human fungal pathogens

Bacterial Multidrug Efflux Pumps at the Frontline of Antimicrobial Resistance: An Overview

Characterization of Increased Extracellular vesicle-Mediated Tigecycline Resistance in Acinetobacter baumannii

Exosomes: A New Pathway for Cancer Drug Resistance

Fungal Extracellular Vesicle-Mediated Regulation: from Virulence Factor to Clinical Application